Chardan Capital downgraded shares of Ariad Pharmaceuticals (NASDAQ:ARIA) from a buy rating to a neutral rating in a report issued on Wednesday, TheFlyOnTheWall.com reports. They currently have $9.00 target price on the stock. The analysts noted that the move was a valuation call. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock opened at $8.48 in last session, and closed at $8.99, while the day range of stock is $8.22 – $9.05. The stock showed a positive weekly performance of 2.98%.
Sequenom, Inc. (NASDAQ:SQNM), a life sciences company providing innovative testing and genetic analysis solutions, reported total revenues of $45.1 million for the fourth quarter and $162.4 million for the full year of 2013. Net loss was $18.9 million , or $0.16 per share, for the fourth quarter and $107.4 million , or $0.93 per share, for the full year. Sequenom, Inc. (NASDAQ:SQNM) stock opened at $2.37, in last session and closed at $2.57, by gaining 10.78%. The 52 week range of the stock is $1.65 – $4.90. Company’s market capitalization is $297.39 million.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) reported fourth quarter 2013 net loss per share of 23 cents, flat year over year. The reported loss was wider than the Zacks Consensus Estimate of a loss of 18 cents. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) stock advanced 6.24% and finished the last session at $16.01. The EPS of the stock remained -0.66. Company’s market capitalization is $531.37 million.
BioDelivery Sciences International (NASDAQ:BDSI) Director Francis Odonnell, Jr. sold 70,000 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) stock opened the session at $8.66, and closed the session at $9.32. The 52 week range of the stock remained $3.52 – $9.50 and the day range was $8.66 – $9.34.